rs4356
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBS1BS2
The NM_000789.4(ACE):c.3281+141T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00169 in 1,342,752 control chromosomes in the GnomAD database, including 33 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.0085 ( 21 hom., cov: 32)
Exomes 𝑓: 0.00083 ( 12 hom. )
Consequence
ACE
NM_000789.4 intron
NM_000789.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.0760
Publications
6 publications found
Genes affected
ACE (HGNC:2707): (angiotensin I converting enzyme) This gene encodes an enzyme involved in blood pressure regulation and electrolyte balance. It catalyzes the conversion of angiotensin I into a physiologically active peptide angiotensin II. Angiotensin II is a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance. This angiotensin converting enzyme (ACE) also inactivates the vasodilator protein, bradykinin. Accordingly, the encoded enzyme increases blood pressure and is a drug target of ACE inhibitors, which are often prescribed to reduce blood pressure. This enzyme additionally plays a role in fertility through its ability to cleave and release GPI-anchored membrane proteins in spermatozoa. Many studies have associated the presence or absence of a 287 bp Alu repeat element in this gene with the levels of circulating enzyme. This polymorphism, as well as mutations in this gene, have been implicated in a wide variety of diseases including cardiovascular pathophysiologies, psoriasis, renal disease, stroke, and Alzheimer's disease. Regulation of the homologous ACE2 gene may be involved in progression of disease caused by several human coronaviruses, including SARS-CoV and SARS-CoV-2. Alternative splicing results in multiple transcript variants encoding both somatic (sACE) and male-specific testicular (tACE) isoforms. [provided by RefSeq, Sep 2020]
ACE Gene-Disease associations (from GenCC):
- renal tubular dysgenesis of genetic originInheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- intracerebral hemorrhageInheritance: Unknown Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00846 (1286/152012) while in subpopulation AFR AF = 0.0298 (1233/41412). AF 95% confidence interval is 0.0284. There are 21 homozygotes in GnomAd4. There are 608 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 21 AR,Unknown gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ACE | NM_000789.4 | c.3281+141T>C | intron_variant | Intron 21 of 24 | ENST00000290866.10 | NP_000780.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00844 AC: 1282AN: 151894Hom.: 20 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
1282
AN:
151894
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.000830 AC: 988AN: 1190740Hom.: 12 AF XY: 0.000707 AC XY: 423AN XY: 598134 show subpopulations
GnomAD4 exome
AF:
AC:
988
AN:
1190740
Hom.:
AF XY:
AC XY:
423
AN XY:
598134
show subpopulations
African (AFR)
AF:
AC:
834
AN:
27268
American (AMR)
AF:
AC:
36
AN:
36040
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
23716
East Asian (EAS)
AF:
AC:
0
AN:
35244
South Asian (SAS)
AF:
AC:
2
AN:
75754
European-Finnish (FIN)
AF:
AC:
0
AN:
42882
Middle Eastern (MID)
AF:
AC:
2
AN:
4786
European-Non Finnish (NFE)
AF:
AC:
16
AN:
893752
Other (OTH)
AF:
AC:
98
AN:
51298
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
53
105
158
210
263
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
26
52
78
104
130
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00846 AC: 1286AN: 152012Hom.: 21 Cov.: 32 AF XY: 0.00818 AC XY: 608AN XY: 74306 show subpopulations
GnomAD4 genome
AF:
AC:
1286
AN:
152012
Hom.:
Cov.:
32
AF XY:
AC XY:
608
AN XY:
74306
show subpopulations
African (AFR)
AF:
AC:
1233
AN:
41412
American (AMR)
AF:
AC:
42
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3468
East Asian (EAS)
AF:
AC:
0
AN:
5158
South Asian (SAS)
AF:
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
AC:
0
AN:
10586
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
2
AN:
67974
Other (OTH)
AF:
AC:
9
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
63
126
189
252
315
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.